MMI 0100 - Moerae Matrix

Drug Profile

MMI 0100 - Moerae Matrix

Alternative Names: MMI-0100

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Moerae Matrix
  • Class Anti-inflammatories; Antifibrotics; Peptides
  • Mechanism of Action MAP-kinase-activated kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis
  • No development reported Fibrosis

Most Recent Events

  • 20 May 2018 Pharmacodynamics data from a phase I trial in Idiopathic pulmonary fibrosis presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
  • 18 May 2018 MMI 0100 is still in phase I trials for Idiopathic pulmonary fibrosis (In volunteers) in Netherlands
  • 18 May 2018 Pooled adverse events and pharmacodynamics data from phase I trials in Idiopathic pulmonary fibrosis presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top